Search PubMed⌕ Search

PubMed · 12787014

Pruritus: scratching the surface.

Abstract

Patients who are jaundiced have an accumulation of bile acids in the plasma, which can cause intense irritation. Pruritus associated with cholestasis is a difficult problem; the pathogenesis remains unknown. In severe cases, it can lead to sleep deprivation and contribute to significant psychological disturbances. Patients who have pancreatic cancer with unrelieved jaundice often say the itching is the worst symptom. Typically patients are prescribed Chlorpheniramine, an antihistamine, and Choleystiramine, which binds bile salts in the bowel and helps to facilitate their excretion. Choleystiramine only works if biliary obstruction is incomplete; it is not very palatable and can cause diarrhoea. A review of the literature revealed that certain drugs not intended for the treatment of pruritus associated with malignant cholestasis eased the symptoms considerably. There was very little relating to skin care in the majority of articles dealing with pruritus. Twycross (1997, Introducing Palliative Care, pp. 112-114) stated that most patients with advanced cancer and pruritus may never need an antihistamine if given appropriate skin care and that drugs are of little use in isolation. A regime of skin care was devised with the main aim of keeping the skin moist and cool. Factors were identified that would alleviate or aggravate the skin surface. With prompt treatment, symptoms were reduced and in some cases eradicated completely. The information gained has led to the planning of a trial to determine efficacy of skin care management and different drug therapies to relieve debilitating pruritus when established treatments fail. Key points include: (1) treatment of pruritus associated with malignant disease is directed towards effective management of the underlying cause; (2) given the subjective nature of pruritus, it is poorly understood and management presents a challenging problem; and (3) effective skin management can help to alleviate debilitating symptoms. Certain drugs not intended for treatment of pruritus associated with malignant cholestasis have proven to be effective.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L Bosonnet. 2003. Pruritus: scratching the surface.. https://doi.org/10.1046/j.1365-2354.2003.00395.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[Molecular mechanisms in the development and progression of pancreas and biliary tract cancers].

Pancreatic and biliary tract cancers are the most lethal malignancies in the gastrointestinal tract. Investigators have actively investigated to elucidate molecular mechanisms involved in the carcinogenesis, growth, invasion and metastasis of these cancers. This review describes those molecular mechanisms and their correlation with clinicopathological features of pancreatic and biliary tract cancers. Furthermore, recent experimental developments in the gene therapy technologies toward these cancers are also summarized.

Biliary Tract Neoplasms↗

Determination of sequential mutation accumulation in pancreas and bile duct brushing cytology.

Neoplastic progression is characterized by clonal expansion of tumor cells associated with accumulation of mutational damage. The timing of mutation acquisition could be of value in distinguishing preneoplastic conditions from early and advanced cancer as well as characterizing tumor aggressiveness and treatment response. Using quantitative methods applied to microdissected cell clusters selected according to cytomorphologic features, we sought to demonstrate the feasibility and efficacy for determining the time and course of mutation accumulation in pancreatobiliary cytology specimens. In all, 40 pancreatic duct and 21 biliary brushing cytology specimens were retrieved from the cytology database. Xylene-resistant markings were placed on the slide underside and coverslips removed. Clusters of benign, atypical and malignant cells were manually microdissected and DNA extracted. Mutations (allelic imbalance) (loss of heterozygosity) were quantitatively determined for a broad panel of 15 markers (1p, 3p, 5q, 9p, 10q, 17p, 17q, 21q, 22q) as well as point mutation in K-ras-2 using PCR/capillary electrophoresis. Time course was based on earlier mutations having a higher proportion of mutant DNA for a particular marker. The descending frequency of detectable mutational involvement in pancreatic cytology was K-ras-2 point mutation (58%), 3p25-26 and 17q21 (35%), 5q23 (33%), 1p36 (28%), followed by the remaining molecular markers. The descending frequency of mutational content in bile duct cytology was 17p13, 1p36, 3p25-26, and 5q23 followed by remaining molecular markers. K-ras-2 point mutation was not seen in bile duct specimens. While there was overlap in the spectrum of mutational markers in pancreatic duct and biliary brushing cytology, the temporal profile was significantly different (P<0.001). Pancreatic and biliary neoplasia progression involves distinct subset of accumulated defined mutations. Determination of timing of the mutational damage in cytologic material could be incorporated in the work-up and help in making a more definitive diagnosis of malignancy in pancreatobiliary cytology specimens.

Biliary Tract Neoplasms↗

Self-expandable metallic stents for malignant biliary obstruction: efficacy on proximal and distal tumors.

AIM: To compare the efficacy of self-expandable metallic stents (EMS) in the treatment of distal and proximal stricture of malignant biliary tumors. METHODS: From March 1995 to June 2004, 61 patients (40 males, 21 females) with malignant biliary obstruction who received self-expandable metallic stent implantation were reviewed retrospectively. The stents were inserted by an endoscopic or percutaneous transhepatic method. We tried to place two stents in the biliary system in T or Y configuration in cases of hilar tumors with bilateral hepatic duct obstruction. The end points of the study were stent occlusion or patient death. RESULTS: The mean time of stent patency was 421 +/- 67 d in the group of proximal stricture (group I) and 168 +/- 18 d in the group of distal stricture (group II). The difference was significant in borderline between the two groups (P = 0.0567). The mean survival time was 574 +/- 76 d in group I and 182 +/- 25 d in group II. There was a significant difference between the two groups (P = 0.0005). CONCLUSION: EMS implantation is a feasible, palliative method for unresectable malignant biliary obstruction. The clinical efficacy of EMS in patients with proximal hilar tumors is better than that in patients with distal tumors.

Biliary Tract Neoplasms↗